TABLE 2.
Absolute mortality rate differences (as percentage of patients) between statin and control arms (by cause) and cancer rates across primary prevention studies
| Study (reference) | CVD death | Non-CVD death | All-cause death | Cancer cases (deaths, where reported) |
|---|---|---|---|---|
| ASCOT-LLA – general (26) | −0.2 | −0.3 | −0.5 | −0.1 (deaths) |
| MRC/HBF HPS – diabetes (28) | NR | NR | NR | NR |
| CARDS (29) | −0.9 | −0.7 | −1.5 | −0.7 (deaths) |
| ALLHAT-LLT (30) | −0.2 | −0.1 | −0.4 | +0.3 |
| PROSPER (31) | −0.7 | +0.5 | −0.2 | +1.6* |
| AFCAPS/TexCAPS (12) | −0.2 | +0.3 | +0.1 | −0.2 |
| WOSCOPS (9) | −0.7 | −0.2 | −0.9 | +0.3 |
– indicates less with statin;
+ indicates more with statin; AFCAPS/TexCAPS Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT-LLT Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial –Lipid-Lowering Therapy; ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm; CARDS Collaborative Atorvastatin Diabetes Study; CVD Cardiovascular disease; MRC/HBF HPS Medical Research Council/British Heart Foundation Heart Protection Study; NR Not reported; PROSPER PROspective Study of Pravastatin in the Elderly at Risk; WOSCOPS West Of Scotland Coronary Prevention Study.
*P<0.05